Close Menu

NEW YORK (GenomeWeb) – Some six months after establishing itself as an independent entity, Olink Proteomics is planning a large expansion of its protein biomarker offerings and exploring the possibility of developing proprietary biomarker content.

The company aims by the end of the year to more than double its current assay offerings, CEO Jon Heimer told GenomeWeb this week. At the same time, it is "dipping its toes" into in-house biomarker development, he added.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Oct
10

This webinar will provide an overview of how a pathology laboratory validated a 77-gene next-generation sequencing-based liquid biopsy assay.

Oct
24

This webinar will tell the story of Versiti’s journey in transforming genetic testing from a manual to a digitized process. It will include detail on how the organization succeeded, pain points along the way, a novel approach to variant assessment, and future plans for the program.